Although in general
NSAIDs do not appear to interact with
antidiabetics (see below)
azapropazone and particularly
phenylbutazone seem to cause a consistent lowering of blood glucose levels (probably by inhibiting the
metabolism of the sulphonylureas), which has resulted in severe hypoglycaemia in a number of cases.
Concurrent use with
phenylbutazone should be well monitored and a reduction in the dosage of the sulphonylurea may be necessary to avoid excessive hypoglycae- mia. The manufacturers of
azapropazone say that the concurrent use of sulphonylureas is not recommended.